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Background and Objectives: The Hancock II bioprosthesis is a second-generation
porcine valve xenograft treated with the detergent sodium dodecyl sulphate (T6) to
retard calcification. The aim of this investigation was to study the gross and
microscopic features in Hancock II explants to assess the structural changes occur-
ring with time.
Methods: Among 1382 Hancock II bioprostheses (701 isolated aortic, 421 isolated
mitral, 130 double) implanted from 1983 to 1997 in 1252 patients, 22 (16 mitral, 6
aortic) were removed at reoperation until 1999 and were available for pathological
investigation: infective endocarditis occurred in 5 and structural deterioration in 8,
whereas in the remaining 9 xenografts reoperation was performed for nonstructural
valve deterioration (paravalvular leak in 4 and prophylactic replacement in 5).
Morphological investigation consisted of gross examination and x-ray, histologic,
immunohistochemistry, electron microscopic, and atomic absorption spectroscopic
examination.
Results: The cause of structural valve deterioration was dystrophic calcification in
4 cases (1 aortic, 3 mitral; range of time graft was in place, 101 to 144 months),
non-calcium–related tears in 3 cases (all mitral, range 121 to 163 months), and
commissural dehiscence in 1 (aortic, range 156 months). Five of the nonstructural
valve deterioration explants (range 42 to 122 months) showed only pinpoint
mineralization at the commissures. Mean calcium content in nonstructural
deterioration explants was 14.70  22.33 versus 99.11  81.52 mg/g in explants
with structural valve deterioration. Electron microscopic examination showed
early nuclei of mineralization mostly consisting of calcospherulae upon cell
debris. Local or diffuse lipid insudation was observed in all but 2 explants and
consisted of cholesterol clefts, lipid droplets, and lipid-laden macrophages
featuring foam cells. The lipid insudation was the most plausible cause of
tearing in 2 explants.
Conclusions: These pathologic findings support the clinical results of a delayed
occurrence of structural failure of Hancock II bioprostheses and a mitigation of
mineralization by the anti-calcification treatment. However, other factors such as
lipid insudation may come into play in the long term.
The Hancock (HCK) II porcine bioprosthesis was introduced in theclinical setting in 1982 with some modifications aimed to enhanceperformance versus the first-generation HCK Standard. The cusptissue is treated with the detergent sodium dodecyl sulphate (T6) toretard calcification, and a low fixation pressure is employed in aneffort to preserve collagen crimping.1
Clinical data suggested that this treatment was successful in significantly im-
proving long-term performance. In particular, mid- and long-term clinical experi-
ence showed improved results in terms of durability and valve-related complications
when compared with HCK Standard.2-4
From the Departments of Cardiovascular
Surgery,a and Pathological Anatomy,b Uni-
versity of Padua Medical School, Padua,
Italy, and Division of Cardiac Surgery,c Ca’
Foncello Hospital, Treviso, Italy.
The study was supported by a grant from
Istituto Superiore di Sanita` and Ministero
Istruzione Universita´ e Ricerca, Rome, It-
aly.
Received for publication Aug 2, 2002; re-
visions requested Sept 18, 2002; revisions
received Nov 14, 2002; accepted for publi-
cation Nov 25, 2002.
Address for reprints: Marialuisa Valente,
MD, Professor, Pathological Anatomy, De-
partment of Pathological Anatomy, Univer-
sity of Padua Medical School, Via A Ga-
belli, 61 35121, Padova, Italy (E-mail:
marialuisa.valente@unipd.it).
J Thorac Cardiovasc Surg 2003;126:99-105
Copyright © 2003 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2003 $30.00  0
doi:10.1016/S0022-5223(03)00131-4
Bottio et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 99
A
CD
The aim of this investigation was to characterize the
pathology and the mode of failure of HCK II explanted
valves, with special reference to onset and progression of
dystrophic calcification and other morphologic changes af-
fecting long-term durability.
Material and Methods
From May 1983 to December 1997, 1382 HCK II bioprostheses
were implanted in 1252 patients: 701 were isolated aortic, 421
isolated mitral, and 130 double-valve replacements. Twenty-two
explants from 22 patients (11 men, 11 women, mean age 64.95 
9.0, range 48 to 76 years) were available for pathological study
because of reoperation performed in the time interval 1988 to
1999. The 22 explants were all of the explants removed during the
study period at these institutions. Evidence of infective endocar-
ditis was found in 5 explants, which were then ruled out from this
study.
The remaining 17 HCK II xenografts (14 mitral and 3 aortic),
explanted from 17 patients, mean age 64.29  10.14 years and in
place from 3 to 163 (mean 94.52  53.46 months) underwent
detailed morphological investigation. Indication for prosthetic re-
placement was incompetence in 9 cases and steno-incompetence in
3, whereas 5 were removed prophylactically during other valve
surgical procedures.
The protocol of investigation consisted of gross examination,
photography of the specimens with a stereoscope, mammography
x-ray for a semiquantitative analysis of Ca deposits using
scores of 0 to 4, histology and immunohistochemistry, transmis-
sion and scanning electron microscopy, and atomic absorption
spectroscopy, as reported elsewhere.5,6
Statistics
The incidence of structural valve deterioration (SVD) in aortic and
mitral positions was compared with the Fisher exact test. The mean
mineralization in SVD and non-SVD explants was compared with
the t test for unequal variances.
Results
Gross Examination and X-ray Findings
SVD was observed in 8 (1 of 831 aortic and 7 of 551 mitral)
explants in place for a mean of 136.0  22.67 months
(range 101 to 163 months) [P (Fisher)  .008].
● Dystrophic calcification (4 explants, 1 aortic and 3
mitral) led to reoperation after 113, 101, 133, and 145
months, respectively. Coarse calcific vegetations with
severe stenosis were observed in a mitral case (Figure
1), while body cusp perforation (Figure 2) and com-
missural tearing with incompetence or steno-incompe-
tence occurred in the remaining 3 cases with x-ray
scores ranging from 3 to 4.
● Primary, non–calcium-related tearing occurred in 3
mitral cases after 121, 156 (Figure 3, a and b), and 163
months. Pinpoint calcification (score 1) was observed
in each, but was not located near tearing.
● A commissural dehiscence, consisting of a detachment
of the commissural aortic wall from the stent post not
related to calcification or infection, was the cause of
incompetence in a mitral bioprosthesis at 156 months
after implantation.
Nine bioprostheses, 7 mitral and 2 aortic, in place for a
mean of 57.66  44.92 months (range 3 to 122) showed no
evidence of structural valve deterioration. Four were ex-
planted because of paravalvular leak after 3, 16, 93, and 106
months (mean 54.5  52.5), and 5 were prophylactically
replaced in the setting of other cardiac surgical valve pro-
cedures after 3, 42, 55, 79, and 122 months (mean 60.2 
44.1). All had pliable cusps with negligible pannus and no
tearing. Four of 9 showed no calcification (score 0 at x-ray)
at a mean time of 19.25  24.6 months (range 3 to 55), and
5 showed initial commissural mineralization (scores 1 to 2)
(Figure 4, a) at a mean time of 88.4  30.4 months (range
42 to 122).
Lipid insudation in the form of yellow spots was ob-
served by the naked eye in 15 explants (Figure 5, a). In 2
explants it was so prominent that most probably accounted
for cusp tearing, in the absence of any other explanation.
Microscopic Findings
At histology fibrinous lining on the cusp surface was focally
present in all cases. A mild fibrous sheathing at the base was
frequently evident and at transmission electron microscopic
examination consisted of myofibroblasts enmeshed in col-
lagen fibers. The surface lacked a true reendothelialization,
occasionally showing lining of platelets.
Focal or scattered mononuclear infiltrates were observed
in all cases just underneath leaflet surface; in only 1 explant
they were seen also deep in the spongiosa.
At transmission and scanning electron microscopic ex-
amination, the elastic and collagen fibers appeared to be
fairly well preserved. In particular collagen fibrils were
regularly banded and arranged in variously oriented fasci-
cles. Native cellular component was poorly preserved.
Cholesterol clefts, sometimes surrounded by mononu-
clear with foreign body-type inflammatory infiltrates, were
seen at histology in 15 explants (Figure 3, c and d, and
Figure 5, b). At transmission electron microscopic exami-
nation, lipid insudation consisted of interstitial lipid drop-
lets, cholesterol needles, and lipid-laden macrophages fea-
turing foam cells (Figure 6).
Calcification was intrinsic and involved both the com-
missural and cuspal body levels (Figure 4, b). In only 1 case
was mineralization observed also upon mild fibrous pannus.
In all cases positive on x-ray, calcification was found at the
ultrastructural level both on cell debris and elastic-collagen
fibers. In addition, calcospherulae and focal collagen calci-
fication were observed also in 2 non-SVD cases even with
score 0 at x-ray. In one instance calcification occurred upon
massive lipid insudation (Figure 5, b, and Figure 6, c).
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Spectroscopic Findings
Mean mineralization in non-SVD explants (prophylactic
and paravalvular leak) was 14.70  22.23 mg/g versus
99.11 81.52 of SVD explants (t test for unequal variances
P  .128).
Discussion
The HCK Standard xenograft was the first commercially
available glutaraldehyde-fixed bioprosthetic valve. Since
the first implantation at the University of Padua in March
1970,7 hundred of thousands were used worldwide.
With time, pathologic studies of explants made clear that
several complications influence bioprosthetic durability.8,9
In 70% of explants, failure was ascribed to dystrophic
calcification, both in form of stiffness and tearing of the
leaflets.10 All the HCK Standard explants, in place for more
than 6 years, appeared more or less “mineralized.” Dystro-
phic calcification appeared to be the main determinant lim-
iting long-term performance, thus becoming a problem for
both patient and surgeon.11 Energy dispersion analysis
showed that the calcific deposits consisted of apatite crys-
tals,5 and ultrastructural investigation demonstrated that
Figure 1. Coarse, polypous calcific deposits at all commissures in a mitral HCK II explant in place for 101 months.
a, Gross outflow view. b, X-ray film.
Figure 2. Calcification with body cusp perforation in an aortic HCK II explant in place for 113 months. a, Gross
inflow view. b, X-ray film.
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early nuclei of calcification occurred in the xenograft cell
membranes and organelles, which were laden of phospho-
lipids.5,12 The latter accounted for the phosphate component
of apatite, whereas the calcium was derived from the extra-
cellular compartment due to loss of membrane imperme-
ability.13 Lessons from these pathological observations
were incorporated into a second-generation valve, the HCK
II, which was presented for the first time at the Second
International Symposium on Cardiac Bioprostheses held in
Rome in 1982.14 The efficacy of the antimineralization
treatment was experimentally proved by subdermal15 and
circulatory implants.16 Implantation in human beings started
in 1982 and included the Toronto, Padova, and Treviso
hospitals. Intermediate-term follow-up gave excellent re-
sults with 100% freedom from bioprosthetic failure at 8
years.2,3
Bortolotti and colleagues,4 by comparing clinical out-
comes of patients with HCK II with those of patients with
the HCK Standard, were able to demonstrate a remarkable
improvement in freedom from SVD at 8 years (100% versus
78  4% in aortic, 100% versus 88  3% in mitral). The
results might have been influenced by the age of the second
series, since patients with HCK Standard differed signifi-
cantly in mean age from those with HCK II (47 12 versus
62  9 years, P  .001).
More recently, David and colleagues17 reported the re-
sults at 15 years with actuarial and actual freedoms from
SVD of 81% and 90% in the aortic group and 66% and 83%
in the mitral group, respectively, thus clearly demonstrating
that HCK II is an improved version of first-generation
porcine valve with extended durability. In particular, the
results were excellent in patients 65 years or older, with
Figure 3. Non– calcium-related tearing in a mitral HCK explant in place for 156 months with massive lipid
infiltration. a, Gross inflow view with yellow spots in the cusps and tearing. b, Negligible calcification on x-ray
film. c, Cholesterol needles at histology (Azan stain 18). d, Close-up of c (Azan stain 36).
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actual freedom from SVD at 15 years of 100% in aortic and
89% in mitral position.
Our clinical and pathologic experience confirms David’s
group’s data that HCK II is a durable porcine valve, more so
in the aortic than in the mitral position, as observed in other
studies. SVD was rare and started to occur 2 to 3 years later
than previously observed in HCK Standard. Valves in the
mitral position began to fail structurally at 8.5 years post-
operatively and valves in the aortic position did not deteri-
orate until 9.5 years postoperatively. One half of the SVD
cases failed because of dystrophic calcification, in the usual
mode of cusp stiffness or tearing.8,9
Half of our specimens were explanted for reasons other
than SVD: perivalvular leak and prophylactic removal.
These explants were of particular interest because it was
possible to detect early occurrence of dystrophic calcifica-
tion, before overt dysfunction. Four of 9 did not show any
evidence of calcification at x-ray, whereas the remaining 5
exhibited pinpoint calcification at commissures as early as
42 months, with 1 explant prophylactically replaced after 10
years. Overall the amount of calcium content was quite low
with a mean of 14.70 22.23 mg/g/dry weight versus 99.11
 81.52 mg/g/dry weight of failed bioprostheses. Evidence
of early onset of calcification at the ultrastructural level was
observed even in a couple of explants showing no mineral-
ization on x-ray. The finding of commissural calcification in
explants without SVD confirms the view that mineralization
starts at the commissural level long before commissural
tearing, thus emphasizing the importance of mechanical
stress in the onset of calcification.
Figure 4. Mitral HCK II explant removed at 122 months from operation due to paravalvular leak. a, X-ray film
showing pinpoint calcification at commissures. b, Nodular intrinsic cusp calcification at histologic examination
(Von Kossa 12).
Figure 5. Prophylactically replaced HCK II aortic explant in place for 79 months. a, Yellow appearance of the
inflow. b, Histology of a leaflet showing diffuse cholesterol clefts and small nodular calcification (hematoxylin-
eosin 18). The adjacent section showed positive results at Von Kossa stain.
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All these observations support the clinical data of an
effectiveness of T6 in delaying mineralization. Nonetheless,
ultrastructural nuclei of mineralization were as usual,
namely upon cell debris and collagen.
In contrast to Butany and colleagues,18 who reported
severe pannus in 60% of failing valves, mainly in mitral
position and often with pannus-related cusp tearing, we had
no case of valve dysfunction due to fibrous tissue over-
growth. Butany and colleagues18 suggested that preserva-
tion at surgery of the subvalvular apparatus favored tissue
ingrowth. This technique was less frequently employed in
our study population.
Although the number of collected explants was limited, it
is noteworthy that we never observed cases of ventricular
free wall laceration,19 inward bending,20,21 cuspal hemato-
ma,22 spontaneous tearing of the cuspal muscle shelf,23 or
thrombosis,24 thus proving that the change of valve design
led to substantial improvement with prevention of many
other complications previously reported in HCK Standard.
Interesting was the single case of commissural dehiscence,
a complication reported in Carpentier Edwards porcine
valve25 but not in the HCK Standard.8,9
The most striking finding of our pathological study was
lipid insudation, which was evident even by naked eye in
the form of yellow spots. At light and electron microscopic
examination, both interstitial lipid droplets and cholesterol
needles as well as lipid-laden macrophages featuring foam
cells were observed and probably accounted for primary
tearing in 2 explants after 12 years of function. Thus lipid
insudation and monocyte infiltrates occur in cuspal tissue of
porcine bioprostheses as seen in early atherosclerosis and
can precipitate SVD in the long-term, even in the absence of
mineralization.26 A cusp torn at commissure by massive
lipid infiltration was reported by our group also in the HCK
Standard.27
T6 treatment removes the lipids from the pig valve at the
time of commercial manufacturing28 but cannot prevent
subsequent lipid insudation, which may also favor calcifi-
cation. Clearly lipid insudation is an acquired, patient-re-
lated problem and as such would likely be seen with other
valves. Thus, with T6 mitigation, dystrophic calcification
may be delayed until other factors, such as lipid insudation,
come into play.
Future prospective and randomized studies as well as
clinical trials should include serum lipid assessment to
establish whether this is a risk factor for SVD. Should a
correlation between serum lipid and risk of SVD be dem-
onstrated, then statins might be indicated in patients having
porcine bioprostheses.
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